Home Neuronal Signaling 5-HT Receptor 억제제 Fluoxetine HCl

연구용

Fluoxetine HCl 5-HT Receptor 억제제

제품 번호S1333

Fluoxetine HCl은 신경 세포막에서 선택적 세로토닌 재흡수 억제제(SSRI)로, 우울증 치료에 사용됩니다.
Fluoxetine HCl 5-HT Receptor 억제제 Chemical Structure

화학 구조

분자량: 345.79

바로가기

품질 관리

배치: 순도: 99.94%
99.94

세포 배양, 처리 및 작업 농도

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
HEK293 Function assay 30 mins Inhibition of human SERT expressed in HEK293 cells assessed as inhibition of serotonin reuptake after 30 mins by fluorescence assay, IC50=0.15μM 22938049
HEK293 Function assay 30 mins Inhibition of human NET expressed in HEK293 cells assessed as inhibition of noradrenaline reuptake after 30 mins by fluorescence assay, IC50=4.41μM 22938049
HEK293 Function assay 30 mins Inhibition of human DAT expressed in HEK293 cells assessed as inhibition of dopamine reuptake after 30 mins by fluorescence assay, IC50=18.4μM 22938049
mammalian cells Function assay Inhibition of human Potassium channel HERG expressed in mammalian cells, IC50=1.51356μM 12873512
JAR Function assay Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells, IC50=0.0324μM 15239661
K562 Cytotoxicity assay Cytotoxicity to reduce chronic myeloid leukemia K 562 cells, CC50=25μM 15267229
U937 Cytotoxicity assay Cytotoxicity to reduce human histolytic lymphoma U937 cells, CC50=33.3μM 15267229
HEK293 Function assay Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells, IC50=0.016μM 16750359
HEK293 Function assay Inhibition of DA transporter expressed in HEK293 cells, IC50=4.4μM 16750359
HEK293 Function assay Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells, IC50=5.2μM 16750359
HEK293 Function assay Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells, IC50=0.016μM 16750363
HEK293 Function assay Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells, IC50=4.4μM 16750363
HEK293 Function assay Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells, IC50=5.2μM 16750363
Jar Function assay Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells, IC50=0.0394μM 16854086
SK-N-MC Function assay Displacement of N-[3H]alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells, Ki=7.3μM 17307358
CHO Function assay Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique, IC50=1.51356μM 18448342
HEK293 Function assay Inhibition of serotonin uptake at human SERT in human HEK293 cells, IC50=0.047μM 18550369
HEK293 Function assay Inhibition of norepinephrine uptake at human NET in human HEK293 cells, IC50=2μM 18550369
HEK293 Function assay Inhibition of dopamine uptake at human DAT in human HEK293 cells, IC50=6μM 18550369
JAR Function assay Inhibition of 5HT uptake at human SERT expressed in human JAR cells, IC50=0.0094μM 18557608
HEK Function assay Inhibition of serotonin uptake at human SERT expressed in HEK cells, IC50=0.047μM 18667309
HEK Function assay Inhibition of norepinephrine uptake at human NET expressed in HEK cells, IC50=2μM 18667309
HEK Function assay Inhibition of dopamine uptake at human DAT expressed in HEK cells, IC50=6μM 18667309
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.01μM 18771916
MDCK Function assay Inhibition of norepinephrine uptake at human NET expressed in MDCK cells, IC50=0.563μM 18771916
Jar Function assay Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells, IC50=0.0394μM 18834188
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.0094μM 18951020
HEK293 Function assay Displacement of [125I]RTI55 from human recombinant SERT expressed in HEK293 cells, Ki=0.0011μM 19014888
HEK293 Function assay Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells, IC50=0.007μM 19014888
HEK293 Function assay Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells, IC50=1.02μM 19014888
HEK293 Function assay Displacement of [125I]RTI55 from human recombinant NET expressed in HEK293 cells, Ki=1.56μM 19014888
HEK293 Function assay Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells, Ki=6.67μM 19014888
HEK293 Function assay Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells, IC50=19.5μM 19014888
HEK293 Function assay Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells by scintillation counting, Ki=0.0011μM 19256502
HEK293 Function assay Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting, IC50=0.0073μM 19256502
HEK293 Function assay Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting, IC50=1.02μM 19256502
HEK293 Function assay Displacement of [125I]RTI-55 from human recombinant NET expressed in HEK293 cells by scintillation counting, Ki=1.56μM 19256502
HEK293 Function assay Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting, Ki=6.67μM 19256502
HEK293 Function assay Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting, IC50=19.5μM 19256502
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in human JAR cells, IC50=0.01μM 19329313
MDCK-Net6 Function assay Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells, IC50=0.563μM 19329313
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in JAR cells, IC50=0.0094μM 19632110
JAR Function assay Inhibition of human SERT expressed in JAR cells, IC50=0.0094μM 19713106
JAR Function assay Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells, IC50=0.0094μM 19722525
HEK293 Function assay Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells, IC50=0.0025μM 20034793
JAR Function assay Inhibition of serotonin uptake at human SERT expressed in human JAR cells, IC50=0.0094μM 20131864
JAR Function assay Inhibition of human SERT expressed in human JAR cells, IC50=0.0094μM 20378347
JAR Function assay Inhibition of SERT-mediated serotonin uptake in human JAR cells, IC50=0.0094μM 20462211
BESM Antitrypanosomal assay 88 hrs Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50=7μM 20547819
BESM Cytotoxicity assay 88 hrs Cytotoxicity against BESM cells after 88 hrs by HTS assay, EC50=16μM 20547819
HEK293 Function assay Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells, IC50=3.1μM 20637635
HEK293 Function assay Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells, IC50=0.0031μM 20724153
HEK293 Function assay Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting, IC50=0.0052μM 21093273
LLC-PK1 Function assay Inhibition of [3H]serotonin reuptake at human recombinant SERT expressed in LLC-PK1 cells by liquid scintillation counting, IC50=0.005012μM 21310612
HEK293 Function assay Inhibition of serotonin reuptake at SERT expressed in HEK293 cells, IC50=0.005012μM 21739935
JAR Function assay Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake, IC50=0.0094μM 21916421
HEK293 Function assay Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells, EC50=0.0027μM 21927645
CHO Function assay Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay, IC50=13.1μM 23121096
HEK293 Function assay 60 mins Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins, Ki=0.0014μM 23403082
HEK293 Function assay 60 mins Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins, IC50=0.0086μM 23403082
HEK293 Function assay 10 mins Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=0.098μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=0.28184μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=1.394μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, Ki=3.764μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=6.30957μM 23602445
HEK293 Function assay 10 mins Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay, IC50=9.12011μM 23602445
HEK293 Function assay Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells, IC50=0.0072μM 24012181
HEK293 Function assay 15 mins Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=0.15μM 24974340
HEK293 Function assay 15 mins Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=4.41μM 24974340
HEK293 Function assay 15 mins Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay, IC50=18.4μM 24974340
HEK293 Function assay 15 mins Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=0.15μM 25221656
HEK293 Function assay 15 mins Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=4.41μM 25221656
HEK293 Function assay 15 mins Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay, IC50=18.4μM 25221656
HEK293 Function assay Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents, IC50=14μM 26588045
tsA201 Function assay Inhibition of of human TREK1 expressed in tsA201 cells assessed as reduction in channel currents, IC50=19μM 26588045
OHS-50 qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells 29435139
MG 63 (6-TG R) qHTS assay qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells 29435139
RD Antiviral assay 5 mins Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 mins under shaking condition and measured after 3 days by neutral red dye-based photometric meth, EC50=1μM 30912944
RD Cytotoxicity assay 3 days Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method, CC50=11.9μM 30912944
Huh7 Antiviral assay Antiviral activity against DENV2 infected in human Huh7 cells by qRT-PCR analysis, IC50=0.38μM 31128447
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성

분자량 345.79 화학식

C17H18F3NO.HCl

 보관 (수령일로부터)
CAS 번호 56296-78-7 SDF 다운로드 원액 보관

동의어 Lilly 110140 HCl, LY-110140 HCl Smiles CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl

용해도

In vitro
배치:

DMSO : 69 mg/mL (199.54 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : 69 mg/mL

Ethanol : 69 mg/mL

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘

Targets/IC50/Ki
5-HT
시험관 내(In vitro)

Fluoxetine은 피할 수 없는 쇼크(IS)로 인한 해마 세포의 세포 증식 하향 조절을 차단합니다.

Fluoxetine은 성체 쥐의 해마 치아회에서 신생 세포 수를 증가시킵니다. Fluoxetine은 또한 전변연 피질에서 증식하는 세포 수를 증가시킵니다.

Fluoxetine은 미성숙 뉴런의 성숙을 가속화합니다. Fluoxetine은 치아회에서 신경생성 의존성 장기 강화(LTP)를 향상시킵니다.

Fluoxetine은 시탈로프람, 플루복사민, 파록세틴, 세르트랄린과는 달리 전전두엽 피질에서 노르에피네프린과 도파민의 세포외 수준을 증가시킵니다. Fluoxetine은 급성 전신 투여 후 노르에피네프린과 도파민의 세포외 농도를 강력하고 지속적으로 증가시킵니다.

생체 내(In vivo)

Fluoxetine 치료는 또한 성체 수컷 Sprague–Dawley 쥐에서 피할 수 없는 쇼크에 노출된 동물에서 관찰된 탈출 잠복기 결핍을 역전시킵니다.

Fluoxetine과 Olanzapine의 병용은 도파민([DA](ex))과 노르에피네프린([NE](ex))의 세포외 수준을 각각 기준선의 361% 및 272%까지 강력하고 지속적으로 증가시키며, 이는 단일 약물보다 현저히 높습니다.

참조
  • [4] https://pubmed.ncbi.nlm.nih.gov/11919662/
  • [5] https://pubmed.ncbi.nlm.nih.gov/10942849/
  • [6] https://pubmed.ncbi.nlm.nih.gov/33441923/

임상시험 정보

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT05634707 Recruiting
Primary Brain Tumor|Brain Tumor Recurrent
Duke University
 August 5 2023 Early Phase 1
NCT04676139 Unknown status
Nocturnal Enuresis
Mansoura University
 July 1 2020 Phase 3
NCT01615055 Withdrawn
Cognitive Dysfunction
University of California Los Angeles|City of Hope Medical Center
 June 2018 Early Phase 1
NCT03390933 Completed
Depression|Hemodialysis-Induced Symptom
MetroHealth Medical Center
 March 1 2018 Phase 4

기술 지원

취급 설명서

Tel: +1-832-582-8158 Ext:3

다른 문의사항이 있으시면 메시지를 남겨주세요.

이름을 입력해주세요.
이메일을 입력해주세요. 유효한 이메일 주소를 입력해주세요.
저희에게 무엇이든 작성해주세요.